Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany’s IQWiG Pans Sanofi’s Lyxumia For Wrong Comparator Choices

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi’s failure to align its comparator selection with that of Germany’s reimbursement authorities has resulted in dismissal of Lyxumia for diabetes type 2, although the company will have an opportunity to challenge the decision.

You may also be interested in...



Emerging Markets, U.S. Provide Better Incubation Environment For Biotech Than Europe, Says Sanofi’s Viehbacher

Taking the helm of EFPIA, Viehbacher says R&D and innovation are the keys to rescuing Europe from its economic slump, but more harmonization across the pharmaceutical sector will be needed too.

Lyxumia As Fourth GLP-1 To Market? Not To Worry, Says Zealand CEO

The Danish biotech has partnerships with major players in several therapeutic areas, including a successful tie-up with Sanofi, and is looking to partner some of its other pipeline programs as well.

NICE Scientific Advice Program May Seek Broader Application Through Boosting Regulator Link-Up

NICE’s scientific advice program, now in its third year, may need refocusing and increased co-operation with regulators to appeal to small and medium-sized companies.

Topics

Related Companies

UsernamePublicRestriction

Register

PS075859

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel